Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced.

Joao Pedro FerreiraStefan D AnkerJaved ButlerGerasimos FilippatosTomoko IwataAfshin SalsaliCordula ZellerStuart J PocockFaiez ZannadMilton Packer

Published in: European journal of heart failure (2022)

Anaemia was associated with poor outcomes. Empagliflozin reduced new-onset anaemia throughout the follow-up and improved HF and kidney outcomes irrespective of anaemia status at baseline.

Keyphrases

iron deficiency
heart failure

left ventricular
metabolic syndrome

adipose tissue

skeletal muscle